These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28502960)

  • 21. Autoantibody reactive with RNA polymerase III in systemic sclerosis.
    Okano Y; Steen VD; Medsger TA
    Ann Intern Med; 1993 Nov; 119(10):1005-13. PubMed ID: 8214977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease.
    Scalapino K; Arkachaisri T; Lucas M; Fertig N; Helfrich DJ; Londino AV; Steen VD; Medsger TA
    J Rheumatol; 2006 May; 33(5):1004-13. PubMed ID: 16583463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.
    Shah AA; Rosen A; Hummers L; Wigley F; Casciola-Rosen L
    Arthritis Rheum; 2010 Sep; 62(9):2787-95. PubMed ID: 20506513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach.
    Van Praet JT; Van Steendam K; Smith V; De Bruyne G; Mimori T; Bonroy C; Elewaut D; Deforce D; De Keyser F
    Rheumatology (Oxford); 2011 Jul; 50(7):1302-9. PubMed ID: 21330340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical relevance of autoantibodies in scleroderma.
    Ho KT; Reveille JD
    Arthritis Res Ther; 2003; 5(2):80-93. PubMed ID: 12718748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis.
    Kuwana M; Kaburaki J; Okano Y; Tojo T; Homma M
    Arthritis Rheum; 1994 Jan; 37(1):75-83. PubMed ID: 8129766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies.
    Koenig M; Dieudé M; Senécal JL
    Autoimmun Rev; 2008 Sep; 7(8):588-93. PubMed ID: 18617021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic sclerosis patients with negative antinuclear antibodies have distinctive clinical manifestations: a multicenter CRDC cohort in China.
    Hui M; Wang X; Zhou J; Zhang L; Duan X; Li M; Wang Q; Zhao J; Hou Y; Xu D; Zeng X
    Z Rheumatol; 2024 Feb; 83(Suppl 1):160-166. PubMed ID: 35852599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis.
    Clark KEN; Campochiaro C; Csomor E; Taylor A; Nevin K; Galwey N; Morse MA; Singh J; Teo YV; Ong VH; Derrett-Smith E; Wisniacki N; Flint SM; Denton CP
    Ann Rheum Dis; 2021 Dec; 80(12):1584-1593. PubMed ID: 34230031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.
    Mierau R; Moinzadeh P; Riemekasten G; Melchers I; Meurer M; Reichenberger F; Buslau M; Worm M; Blank N; Hein R; Müller-Ladner U; Kuhn A; Sunderkötter C; Juche A; Pfeiffer C; Fiehn C; Sticherling M; Lehmann P; Stadler R; Schulze-Lohoff E; Seitz C; Foeldvari I; Krieg T; Genth E; Hunzelmann N
    Arthritis Res Ther; 2011; 13(5):R172. PubMed ID: 22018289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma.
    Toki S; Motegi S; Yamada K; Uchiyama A; Kanai S; Yamanaka M; Ishikawa O
    J Dermatol; 2015 Mar; 42(3):283-7. PubMed ID: 25582037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis.
    Costa S; Mondini M; Caneparo V; Afeltra A; Airò P; Bellisai F; Faggioli P; Gerli R; Lotzniker M; Meroni PL; Morozzi G; Radice A; Riccieri V; Scarsi M; Sebastiani GD; Sinico RA; Tincani A; Gariglio M; Landolfo S
    Rheumatology (Oxford); 2011 Apr; 50(4):674-81. PubMed ID: 21134960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil].
    Coelho Horimoto AM; da Costa IP
    Rev Bras Reumatol; 2015; 55(3):229-39. PubMed ID: 25559063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies.
    Airo' P; Ceribelli A; Cavazzana I; Taraborelli M; Zingarelli S; Franceschini F
    J Rheumatol; 2011 Jul; 38(7):1329-34. PubMed ID: 21459934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.
    Patterson KA; Roberts-Thomson PJ; Lester S; Tan JA; Hakendorf P; Rischmueller M; Zochling J; Sahhar J; Nash P; Roddy J; Hill C; Nikpour M; Stevens W; Proudman SM; Walker JG
    Arthritis Rheumatol; 2015 Dec; 67(12):3234-44. PubMed ID: 26246178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?
    Benyamine A; Bertin D; Heim X; Granel B; Bardin N
    Eur J Intern Med; 2017 Oct; 44():e42-e44. PubMed ID: 28781194
    [No Abstract]   [Full Text] [Related]  

  • 38. The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud's phenomenon.
    Pavlov-Dolijanovic SR; Damjanov NS; Vujasinovic Stupar NZ; Baltic S; Babic DD
    Rheumatol Int; 2013 Dec; 33(12):2967-73. PubMed ID: 23934522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroenzymeimmunoassay to detect systemic sclerosis-associated antibodies: diagnostic performance and correlation with conventional techniques.
    Bonroy C; Smith V; Van Steendam K; Van Praet J; Deforce D; Devreese K; De Keyser F
    Clin Exp Rheumatol; 2012; 30(5):748-55. PubMed ID: 22765957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Very early diagnosis of systemic sclerosis.
    Bellando-Randone S; Guiducci S; Matucci-Cerinic M
    Pol Arch Med Wewn; 2012; 122 Suppl 1():18-23. PubMed ID: 23222375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.